Fig. 1 | British Journal of Cancer

Fig. 1

From: Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis

Fig. 1

a Unsupervised hierarchical clustering of normalized and z-score transformed SWATH-MS protein peak areas; * classification based on 10 day MEK inhibition cell viability. b 2D PCA projection of melanoma cell lines based on SWATH-MS protein peak areas identifies two clusters. c Concentration response curves of the ten melanoma cell lines after ten-day exposure to MEK inhibitor selumetinib (AZD6244). d Cell viability after 10 day exposure to 2 µM selumetinib (MEKi). Orange—nominal MEKi resistant, Blue—nominal MEKi sensitive based on PCA clusters

Back to article page